---
title: "Structure Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285621625.md"
datetime: "2026-05-07T21:14:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285621625.md)
  - [en](https://longbridge.com/en/news/285621625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285621625.md)
---

# Structure Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EBIT: As of FY2026 Q1, the actual value is USD -89.38 M.

#### Cash Position

Structure Therapeutics Inc. reported cash, cash equivalents, and short-term investments totaling $1,458.5 million as of March 31, 2026 . The company received $100.0 million in the first quarter of 2026 from an upfront license fee for certain patents .

#### Research and Development (R&D) Expenses

R&D expenses for the first quarter of 2026 were $66.5 million, an increase compared to $42.9 million for the same period in 2025 . This rise was primarily attributed to increased clinical trial costs, preclinical research and development expenses, and higher employee expenses due to an increase in personnel .

#### General and Administrative (G&A) Expenses

G&A expenses for the first quarter of 2026 were $22.9 million, up from $13.4 million in the first quarter of 2025 . The increase was mainly due to higher employee expenses as the company expanded its infrastructure and professional services .

#### Net Loss

Structure Therapeutics Inc. reported a net loss of - $76.0 million for the first quarter of 2026, which included a non-cash share-based compensation expense of $11.6 million . This compares to a net loss of - $46.8 million for the same period in 2025, which included a non-cash share-based compensation expense of $5.9 million .

#### Operational Metrics

Structure Therapeutics Inc. reported positive results from the aleniglipron Phase 2 ACCESS II study, showing a placebo-adjusted mean weight loss of 16.3% (at 180 mg dose) and 16.0% (at 240 mg dose) at 44 weeks . The ongoing ACCESS OLE study demonstrated continued weight loss of up to 16.2% (at 120 mg dose) at 56 weeks, with no weight loss plateau observed in any studies . The company also received positive end-of-Phase 2 feedback from the FDA for aleniglipron, including clear guidance on the Phase 3 program . In December 2025, ACCG-2671, an oral small molecule amylin therapy, advanced into a Phase 1 clinical study . In November 2025, ACCG-3535 was declared as a second oral small molecule dual amylin calcitonin receptor agonist development candidate .

#### Outlook / Guidance

Structure Therapeutics Inc. expects data from the ACCESS OLE study in Q3 2026 and from the Body Composition and Type 2 Diabetes / Obesity studies in Q4 2026, with the aleniglipron Phase 3 program anticipated to initiate in Q3 2026 . Initial data from the Phase 1 SAD study of ACCG-2671 and initiation of its MAD study are expected in Q3 2026, while Phase 1 initiation of ACCG-3535 is projected for Q4 2026 . The company expects its current cash, cash equivalents, and short-term investments to fund projected operations and key clinical milestones through the end of 2028 . Additionally, Structure Therapeutics Inc. amended its Sales Agreement to increase the At-The-Market (ATM) Shares available for sale by an additional $150,000,000, for an aggregate offering price of up to $400,000,000, having already sold 3,040,000 ATM Shares for gross proceeds of approximately $58,520,000 under the original agreement .

### Related Stocks

- [GPCR.US](https://longbridge.com/en/quote/GPCR.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Richards Group Inc. Announces May 2026 Dividend | RPKIF Stock News](https://longbridge.com/en/news/286925142.md)
- [Hemab Therapeutics Reports First Quarter 2026 Financial Results](https://longbridge.com/en/news/287208997.md)